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Genetic testing in children raises many important ethical, legal, and social issues. One of the main concerns is the ethically
inappropriate genetic testing of minors. Various European countries established professional guidelines which reﬂect the diﬀerent
countries perspectives regarding the main ethical issues involved. In this paper, we analyze the Italian and the British guidelines by
highlighting diﬀerences and similarities. We discuss presymptomatic, predictive, and carrier testing because we consider them to
be the more ethically problematic types of genetic testing in minors. In our opinion, national guidelines should take into account
the diﬀerent needs in clinical practice. At the same time, in the case of genetic testing the national and supranational protection of
minors could be strengthened by approving guidelines based on a common framework of principles and values. We suggest that
the Oviedo Convention could represent an example of such a common framework or, at least, it could lead to articulate it.
1.Introduction
Genetic testing of minors raises many important ethical
issues [1–4]. It can often generate information about future
impairments in children’s health without helping physicians
to establish diagnostic and/or therapeutic processes. First of
all, we should consider the impact of genetic tests on the
child: they may lead to stigmatization and they could change
the day-to-day family’s life. Moreover, the child may also
feel depressed or worried about the possible consequences of
his/her genetic disorders, especially when it is not clear how
they will aﬀect their future [5, 6]. Another important issue
concerns the child’s right not to know, by considering that
minors have the right to participate in the medical decision-
making process.
In Article 12 of the United Nations “Convention on the
Rights of the Child” we read that a “child who is capable
of forming his or her own views [has] the right to express
those views freely in all matters aﬀecting the child, the views
of the child being given due weight in accordance with the
age and maturity of the child” [7]. It is important to bear
in mind that, in the case of genetic testing, as well as in the
case of similar issues in medicine, the child’s privacy and
conﬁdentiality need to be respected [8–10].
In many countries, national guidelines have been devel-
oped. They address various aspects of childhood testing
[1, 2, 11]. In our opinion, it could be interesting to ques-
tion whether there are any national cultural factors or par-
ticular policies which could contribute to approach the topic
diﬀerently.
Geneticinformationchallengestheindividualisticnature
of many moral assumptions made in discussing issues in
medicalethics,becauseofthefamilialnatureofmuchgenetic
data. On the one hand, in the UK, the Human Genetics
Commission was established partly in response to the public
intuition that genetic information is especially private: its
more recent work [12] reﬂects both scientiﬁc developments
in genetics and the policy pressures to make ever more use of
genetic information. In particular, issues include the increas-
ing preimplantation genetic diagnoses, direct-to-consumer
genetic testing, and government plans to expand the national
DNA database for forensic purposes.
On the other hand, in Italy, where the historical and cul-
turalheritageofCatholicismisanintegralelementofnation-
al identity and where the multicultural approach to medical
issues is increasing, great importance is given to the social,
religious,andfamilialimplicationofgeneticcounseling.Fur-
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disease and disability, on self-determination, and on living
in a just and inclusive society [13].
In this paper, we study these two diﬀerent approaches by
considering two guidelines as examples. They are the Guide-
linesforthe“GeneticTestingofChildren”oftheBritishSoci-
ety for Human Genetics (BSHG) [14] and the “Guidelines
for Medical Genetics Activities” of the Italian Permanent
Conference for Relations between the State and the Regions
and Autonomous Provinces of Trent and Bolzano [15]. We
focus our attention on presymptomatic, predictive, and car-
rier testing because they raise major ethical concerns.
Carrier tests are used to determine whether an individ-
ual carries a mutated gene or a balanced chromosomal rear-
rangement. Two are the main ethical issues concerning car-
rier tests: ﬁrst, the information about carrier status does
not provide immediate medical beneﬁt to the minor who is
tested; second, this type of testing may violate the minor’s
rights of privacy, conﬁdentiality, and autonomous decision-
making in adulthood [11].
Presymptomatic and predictive genetic testing refers to
the possibility of ﬁnding a genetic alteration before the ap-
pearance of symptoms related to that alteration. Testing
young people for adult-onset disorders is the most contro-
versial predictive testing because we do not know yet any
treatment that could prevent the onset and progression of
the disease [16]. In this case, if the test is predictive and there
are no direct or immediate medical beneﬁts available, we are
left only with the possibility of deciding whether to perform
a genetic test on a minor and, in the aﬃrmative, when and
how we should perform it.
For the purposes of the present paper, we use “minor”
and “child” as synonymous, according to Article 1 of the
United Nations “Convention on the Rights of the Child” [7]
which states that “a child means every human being below
the age of eighteen years unless, under the law applicable to
the child, majority is attained earlier” and considering that,
both in Italy and in the UK, majority is reached at 18 years
old.
2.MaterialsandMethods
We analyze the Guidelines for the “Genetic Testing of Chil-
dren” of the BSHG and the document entitled “Guidelines
for Medical Genetics Activities” of the Italian Conference
State-Regions because they are two ethically relevant docu-
ments. In particular, we highlight both their common and
diﬀerent ethical choices.
The 2010 BSHG report was prepared by professionals
working in human genetics in the UK. It revisited the issues
explored in 1994 by the Clinical Genetic Society in light of
subsequent developments and of the other guidelines pub-
lished since 1994.
The Italian guidelines were approved in 2004 by the
Permanent Conference for Relations between the State and
the Regions and Autonomous Provinces of Trent and Bol-
zano. This Conference is an important body where a con-
tinued dialogue is maintained between the State and Regions
on various health-care issues in relation to the whole sys-
tem of local self-government; it also facilitates cooperation
between central government, local authorities, and regions.
The Italian guidelines were set up to provide common and
harmonized national directives in medical genetics. They
aimed at assuring to Italian citizens the beneﬁts of proper
levels of assistance and quality in performing genetic tests.
3. Results and Discussion
According to both guidelines, the ethically more relevant
aspects in performing genetic testing on minors are the
timing of performing predictive or presymptomatic tests, the
possibilityofperformingcarriertesting,andtheinvolvement
of the minor in the decision-making process by helping him
or her to understand the meaning and the purpose of the test
results.
One of the main controversial issues is the capacity to
perform predictive or pre-symptomatic testing on asymp-
tomatic minors. The BSHG guidelines recommend that
“in such circumstances testing should normally be delayed
until the young person can decide for him/herself when, or
whether, to be tested” [14]. They also state that “this does
not mean that childhood testing for such conditions should
never be done” [14]. They justify their recommendation
by explaining that testing in childhood may aﬄict future
autonomous decisions. It is also recommended that, when
a parent requests to have a child tested and this test has
no direct or immediate medical beneﬁts, “an assessment
should be made of the balance of harms and beneﬁts” [14]
by considering the child’s best interests as the basis of the
decision-making process.
Paragraph 4.1 of the Italian guidelines is entitled “Tests
on Minors.” There we read that presymptomatic tests should
be deferred until the minors reach legal maturity (i.e., 18
years old in Italy). These genetic tests, however, can be
performed on a minor with the consent of both parents (or
of the legal guardian) when there are current and concrete
therapeutic or preventive possibilities. In this paragraph,
great attention is paid to the psychological consequences of
this type of testing, such as the eﬀects on the minor’s self-
esteem, the possible changes in the parent-child relation-
ship, the stigmatization of healthy brothers or sisters, the
stigmatization of the minor in the educational setting, and
the possible consequences on his/her future career, as well as
emotional implications.
With respect to this topic, we conclude that, both in
Italy and in the UK, these guidelines recommend that the
availability of therapeutic or preventive measures be a pre-
requisite for testing asymptomatic minors, regardless of age.
Tests with no current beneﬁts for children are to be deferred
until the minor is 18 years old.
Regarding any genetic condition which is likely to oc-
cur during childhood, the BSHG guidelines suggest a cau-
tious approach. There may be good reasons to defer testing,
while in the Italian guidelines there are no speciﬁc recom-
mendations on this aspect.
Regarding genetic testing to establish if a minor is carrier
of a speciﬁc gene, the Italian guidelines discourage only
prenatal tests by considering that, in the vast majority of cas-
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a female carrier of an X-linked recessive mutation has no
implications for the child’s health (other than related to fut-
ure reproductive choices). But testing is accepted when both
parents are carriers of the gene causing a speciﬁc disease and
when there is the concrete possibility that their child carries
that disease.
In the BSHG guidelines, carrier testing is examined in
Part C by discussing a clinical case (no. ﬁve). The scenario is
the following: a couple had their child tested with a newborn
screening program for cystic ﬁbrosis (CF)—an autosomal
recessive condition in which aﬀected children carry two
altered copies of the CF gene. The father and the baby are
found to be carriers, while the mother is not. The couple has
two other children, aged 6 and 8 years old. They request their
children to be tested and learn that they are also carriers. The
ensuing discussion focuses on the following aspects: “testing
for carriers of sex-linked and chromosomal disorders is often
a weightier matter than for autosomal recessive disease...it is
appropriateforprofessionalstoconsiderthetimingoftesting
for carrier status of sex-linked and chromosomal disorders
rather more carefully than for most autosomal recessive
conditions” [14]. Moreover, “it is important that the young
person is adequately informed about their reproductive risks
and we believe this is more likely to be the case if they
themselves are closely involved in any decision about genetic
testing”[14].Thus,carriertestingisallowed,especiallyforX-
linked or chromosomal disorders, whether or not the test is
performed on minors. Health-care professionals and genetic
counselors are expected to support families in discussing
the situation with the child as he/she grows up and reaches
maturity.
In the BSHG guidelines, great importance is given to
discussing with “all relevant parties” [14] the timing of
predictive testing. But the identity of these relevant parties
is not speciﬁed: they might be the child’s parents, but, in
the case of genetic information, other family members could
be involved. Hence, health-care professionals are left with
uncertainty about who should be involved in the decision-
making process. In particular, point 6 of Part A states
that health-care professionals should facilitate “discussions
within the family” [14], without specifying the meaning of
the word “family” in this context.
Paragraph 2 of the Italian guidelines aﬃrms that “The
process of genetic counseling aims at helping the person and
the family” [15] to understand all the medical information
regarding the test and its possible consequences, without
specifying the role of minors in this information process. Yet,
the paragraph notes that the process of genetic counseling
may have important ethical and psychological consequences
for minors, particularly related to reproductive choices and
to the possibility for the minor of knowing or not knowing
his/hergeneticfeaturesandtheirfutureeﬀects.Inthiscase,it
seems that no attention is given to people who cannot make
autonomous decisions and who might not be well aware
of the consequences of a speciﬁc genetic mutation, such as
young children. This approach is representative of the lack of
attention in the Italian health-care setting to inform minors
and to promote their role in the decision-making process.
Hence, we stress the need for more binding provisions and
for a better cooperation among health-care professionals.
When we reﬂect on genetic information, the BSHG
guidelines emphasize the importance of parents talking to
their children about their family history from a young age.
We believe that this could lead to controversial situations in
dailyfamilylife.Sometimes,itmightbediﬃculttoexplainto
one’s child the “family history.” At an earlier stage of devel-
opment, this history might inﬂuence negatively the child’s
development. It could be advisable to wait until the minor
is older.
According to paragraph 3.3 of the Italian guidelines, in
case of minors the genetic information should be given only
to the parents. To them, it should also be speciﬁed “the
reason why the test can be helpful, the pros and cons of the
test, the possible limits of the results, and the implications
for the patients and other family members”. Additionally,
it is important to ensure the patient’s capability of making
autonomous decisions on the basis of his/her values. Minors,
however, might not be able to make autonomous decisions
because their whole set of values is not yet fully established.
Their role in the decision-making process might not be
proactive. Paragraph 7.2 aﬃrms that genetic counseling is
of great importance for patients who cannot read or cannot
understand written documents. Is it possible to extend this
provision to children who do not yet read or to minors with
developmental or speech impairment?
Finally, in either set of guidelines it is not clear how the
decision-making process should be performed when those
with responsibility of caring for the child cannot come to
an agreement. This might occur frequently in daily practice,
especially when we remember that discovering about one’s
child genetic mutations might increase the parents’ anxiety,
depression, and suﬀering; it could also lead to conﬂicts
between parents concerning how to proceed.
4. Conclusion
Decisions about the timing of genetic testing raise diﬀerent
diﬃculties for parents, children, and health-care profession-
als. Regarding predictive tests, in order to protect the privacy
and conﬁdentiality of genetic information and the minor’s
right not to know, the British and Italian guidelines suggest
to postpone testing asymptomatic children, when there is no
urgent medical need. The BSHG guidelines support testing
when the minor can participate in the decision-making pro-
cess, while the Italian guidelines propose that this type of test
be deferred until the minor reaches the age of 18 years old.
Carrier testing is approached diﬀerently in both guide-
lines. The Italian document suggests that this kind of anal-
ysis should not to be performed, except in the case of pre-
natal diagnosis when both parents are carriers and when
there is a relevant risk for the child to be aﬀected. The Bri-
tish approach is quite diﬀerent: carrier testing could be per-
formed, especially for X-linked and chromosomal disorders,
and health-care professionals should facilitate the family’s
decision-making process.
Both guidelines lack details about the role of minors in
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leftontheirowntoformtheirownjudgmentsinlightoftheir
values, by deciding who, among the family members, should
be involved, whether or not directly inform the minor, how
and when to inform the child. Moreover, British guidelines
give importance to the communication process between
parents and minors, while Italian provisions emphasize the
role played by health-care professionals and parents. It is
interesting to notice that neither in the BSHG guidelines nor
in the Italian ones there are recommendations about how to
address possible conﬂicts between those entitled to care for
the child.
One could argue that diﬀerences in national professional
guidelines can enrich the debate and respond to speciﬁc
and peculiar instances in the day-by-day clinical practice.
Nevertheless, we think that these diﬀerences and similarities
in attitudes between the Italian and British professional
guidelines should be further examined to ensure the protec-
tion of vulnerable people in the European context. In our
opinion,indevelopingnationalguidelinesongenetictesting,
we should take into account diﬀerences in clinical practice,
but a common eﬀort is needed to assure the protection of
minors. Hence, the approval and the application of national
guidelines should be promoted. These guidelines should also
express a common framework of principles and values.
As a concluding example, regarding information and
consentinmedicaltreatmentsinvolvingminors,webelieveit
isinterestingtounderlinetheimportanceofthe“Convention
for the Protection of Human Rights and Dignity of the
Human Being with regard to the Application of Biology
and Medicine” [17]. This Convention was adopted by the
Committee of Ministers of the Council of Europe in No-
vember 1996 and it was opened for signature in Oviedo
(Spain) on 4 April 1997. It aims at providing a common
framework for the protection of human rights and human
dignity in biology and medicine. In article 6, the Convention
establishes that “Where, according to law, a minor does not
have the capacity to consent to an intervention, the inter-
vention may only be carried out with the authorization of
his or her representative or an authority or a person or
body provided for by law.” Moreover, “The opinion of the
minor shall be taken into consideration as an increasingly
determiningfactorinproportiontohisorherageanddegree
of maturity” [17].
WethinkthattheConventionfocusonrightsandhuman
dignity, as well as its speciﬁc proposals, could be useful to
promote dialogue and interaction between diﬀerent cultural
approaches, such as the two analyzed in this article, even
being aware that the UK is not a signatory of the Oviedo
Convention. In conclusion, we acknowledge the ethical com-
plexity of deciding on the timing of genetic tests in the case
of minors. We emphasize our desire for articulating proce-
dural guidelines—national and supranational—and for their
implementation to help us in practicing genetic medicine
within our society.
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